A Phase 1a Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults

Trial Profile

A Phase 1a Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2016

At a glance

  • Drugs MEDI 7510 (Primary) ; RSV F protein vaccine
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; First in man
  • Sponsors MedImmune
  • Most Recent Events

    • 19 Apr 2016 Results published in the Vaccine
    • 10 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Mar 2015 Planned number of patients changed from 200 to 144 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top